Statin response and pharmacokinetics variants

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 8, 2005, Pages 1291-1297

  Kajinami, Kouji ^a   Masuya, Hiroshi ^a   Hoshiba, Yachiyo ^a   Takeda, Kenji ^a   Sato, Ryoko ^a   Okabayashi, Mizuho ^a   Schaefer, Ernst J ^b,c  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor (statin); Adverse event; Low density lipoprotein cholesterol; Pharmacogenetics; Pharmacokinetics

Indexed keywords

ABC TRANSPORTER A1; ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CLINICAL PRACTICE; DNA POLYMORPHISM; DRUG DISPOSITION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; ISCHEMIC HEART DISEASE; PHARMACOLOGICAL PARAMETERS; PHENOTYPE; PREDICTION; PRIMARY PREVENTION; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT;

CYTOCHROME P-450 ENZYME SYSTEM; GENETIC MARKERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LINKAGE (GENETICS); MEMBRANE TRANSPORT PROTEINS; PHARMACOGENETICS; VARIATION (GENETICS);

EID: 22744440247     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.8.1291     Document Type: Review

References (56)

1. NCEP: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung and Blood Institute. (2002) NIH Publication No. 02-5215.
2. THIRD JOINT TASK FORCE OF EUROPEAN AND OTHER SOCIETIES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE: Executive summary of European guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. (2003) 24:1601-1610.
3. GENEST J, FROHLICH J, FODOR G, MCPHERSON R, THE WORKING GROUP ON HYPERCHOLESTEROLEMIA AND OTHER DYSLIPIDEMIAS: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can. Med. Assoc. J. (2003) 169:921-924.
4. HATA Y, MABUCHI H, SAITO Y et al.: Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J. Atheroscler. Thromb. (2002) 9:1-27.
5. ENDO A: The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. (1992) 33:1569-1582.
6. BROWN MS, GOLDSTEIN JL: A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 232:34-47.
7. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (1995) 333:1301-1307.
8. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615-1622.
9. SEVER PS, DAHLÖF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet (2003) 361:1149-1158.
10. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY WRITING GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
11. SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med. (1996) 335:1001-1009.
12. THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. (1998) 339:1349-1357.
13. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet (2002) 360:7-22.
14. SHEPHERD J, BLAUW GJ, MURPHY MB et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360:1623-1630.
15. INTERNATIONAL HUMAN GENOME SEQUENCING CONSORTIUM: Initial sequencing and analysis of the human genome. Nature (2001) 409:860-921.
16. VENTER JC, ADAMS MD, MYERS EW et al.: The sequence of the human genome. Science (2001) 291:1304-1351.
17. WEINSHILBOUM R: Inheritance and drug response. N. Engl. J. Med. (2003) 348:529-537.
18. EVANS WE, MCLEOD H: Pharmacogenomics. Drug disposition, drug targets, and side effects. N. Engl. J. Med (2003) 348:538-549.
19. KALOW E, TANG BK, ENDRENYI I: Hypothesis: comparison of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics (1998) 8:283-289.
20. RODEN DM, GEORGE AL Jr: The genetics of variability in drug responses. Nat. Rev. Drug. Discov. (2002) 1:37-44.
21. MAITLAND-VAN DER ZEE AH, KLUNGEL OH, STRICKER BHC et al.: Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Athersoclerosis (2002) 163:213-222.
22. HUUMA LM, TERRA SG: Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. Am. J. Health. Syst. Pharm. (2002) 59:1241-1252.
23. SCHMITZ G, DROBNIK W: Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin. Chem. Lab. Med. (2003) 41:581-589.
24. KAJINAMI K, TAKEKOSHI N, BROUSSEAU ME, SCHAEFER EJ: Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis (2004) 177:219-234.
25. ZINEH I: HMG-CoA reductase inhibitor pharmacogenetics: overview and implications for practice. Future Cardiology (2005) 1:191-206.
26. KAJINAMI K, TAKEKOSHI N, SAITO Y: Pitavastatin: efficacy and safety profile of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev. (2003) 21:199-215.
27. BOLEGO C, BAETTA R, BELLOSTA S, CORSINI A, PAOLETTI R: Safety considerations for statins. Curr. Opin. Lipidol. (2002) 13:637-644.
28. KAJINAMI K, BROUSSEAU ME, ORDOVAS JM, SCHAEFER EJ: CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. (2004) 93:104-107.
29. WANG A, YU BN, LUO CH et al.: Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur. J. Clin. Phamacol. (2005) 60:843-848.
30. CHASMAN DI, POSADA D, SUBRAHMANYAN L, COOK NR, STANTON JR VP, RIDKER PM: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 291:2821-2817.
31. HUSTERT E, HABERL M, BURK O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics (2001) 11:773-779.
32. KIVISTO KT, NIEMI M, SCHAEFFELER E et al.: Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 14:523-525.
33. MULDER AB, VAN LIJF HJ, BON MAM et al.: Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin. Pharmacol. Ther. (2001) 70:546-551.
34. GEISEL J, KIVISTO KT, GRIESE EU, EICHELBAUM M: The efficacy of simvastatin is not influenced by CYP2D6. Clin. Pharmacol. Ther. (2002) 72:595-596.
35. KIRCHHEINER J, KUDLICZ D, MEISEL C et al.: Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther. (2003) 74:186-194.
36. HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97:3473-3478.
37. BOGMAN K, PEYER AK, TOROK M, JUSTERS E, DREWE J: HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. (2001) 132:1183-1192.
38. KAJINAMI K, BROUSSEAU ME, ORDOVAS JM, SCHAEFER EJ: Multidrug resistance-1 gene (MDR1) polymorphisms influence the response to atorvastatin treatment in a gender specific manner. Am. J. Cardiol. (2004) 93:1046-1050.
39. NIEMI M, SCHAEFFELER E, LANT T et al.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 14:429-440.
40. HSIANG B, ZHU Y, WANG Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liverspecific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. (1999) 274:37161-37168.
41. NAKAI D, NAKAGOMI R, FURUTA Y et al.: Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacot Exp. Ther. (2001) 297:861-867.
42. SHITARA Y, ITOH T, SATO H, LI AP, SUGIYAMA Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporine A. J. Pharmacol. Exp. Ther. (2003) 304:610-616.
43. BOLEGO C, POLI A, CIGNARELLA A, CATAPANO AL, PAOLETTI R: Novel statins: pharmacological and clinical results. Cardiovasc. Drugs Ther. (2002) 16:251-257.
44. FUJINO H, NAKAI D, NAKAGOMI R, SAITO M, TOKUI T, KOJIMA J: Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor fo HMG-CoA reductase. Arzneimittelforschung (2004) 54:382-388.
45. KIM BR: 3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: What's it all about? Clin. Pharmacol. Ther. (2004) 75:381-385.
46. NISHIZATO Y, IEIRI I, SUZUKI H et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. (2003) 73:554-565.
47. IWAI M, SUZUKI H, IEIRI I, OTSUBO K, SUGIYAMA Y: Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics (2004) 14:749-757.
48. MWINYI J, JOHNE A, BAUER S, ROOTS I, GERLOFF T: Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1 haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. (2004) 75:415-421.
49. TAKEDA M, NOSHIRO R, ONOZATO HL et al.: Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur. J. Phamacol. (2004) 483:133-138.
50. PRUEKSARITANONT T, SUBRAMANIAN R, FANG X et al.: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. (2002) 30:505-512.
51. PRUEKSARITANONT T, TANG C, QIU Y, MU L, SUBRAMANIAN R, LIN JH: Effect of fibrates on metabolism of statins in humans hepatocytes. Drug Metab. Dispos. (2002) 30:1280-1287.
52. ISHIKAWA C, OZAKI H, NAKAJIMA T et al.: A frameshift variant of CYP2C8 in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J. Hum. Genet. (2004) 49:582-585.
53. SHITARA Y, SATO H, SUGIYAMA Y: Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Ann. Rev. Pharmacol. Toxicol. (2005) 45:689-723.
54. KAJINAMI K, BROUSSEAU ME, ORDOVAS JM, SCHAEFER EJ: Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis (2004) 175:287-293.
55. KAJINAMI K, BROUSSEAU ME, LAMON-FAVA S, ORDOVAS JM, SCHAEFER EJ: Gender-specific effects of estrogen receptor α gene haplotype on lipid response to atorvastarin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis (2005) 178:331-338.
56. KAJINAMI K, BROUSSEAU ME, ORDOVAS JM, SCHAEFER EJ: A promoter polymorphism in cholesterol 7α-hydroxylase interacts with apolipoprotein E genotype in the LDL cholesterol-lowering response to atorvastarin. Atherosclerosis (2005) 180(2):407-415.